comparemela.com

Latest Breaking News On - Georgina mowatt - Page 1 : comparemela.com

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7 3 in Biochemical Recurrence of Prostate Cancer

- Oral presentation based on Late-breaking Abstract featured at American Urological Association's 2022 Annual Meeting (AUA2022) - Blue Earth Diagnostics, a Bracco company and recognized leader in

United statesUnited kingdomScintomics gmbKostenloser wertpapierhandelGeorgina mowattMarkt flemingDavide gaudenMike beyerPriscilla harlanStudy groupDrug administrationAmerican urological associationSam brown incBracco groupTechnical university of munichVirginia oncology associates

Blue Earth Therapeutics Announces U S FDA Clearance for Investigational New Drug (IND) Application

− 177Lutetium-labelled radiohybrid Prostate-Specific Membrane Antigen (177Lu-rhPSMA-10.1) is a highly optimized, next generation therapeutic radiopharmaceutical −− Newly launched Blue Earth Therapeutics rapidly advancing lead candidate into Phase 1/2 clinical development –OXFORD, United Kingdom & BURLINGTON, Mass. .

United statesUnited kingdomScintomics gmbGeorgina mowattDavide gaudenMike beyerPriscilla harlanCompany investigational new drug applicationDrug administrationSam brown incBracco groupTechnical university of munichNuclear medicineCorporate communicationsProstate specific membrane antigenBlue earth therapeutics

Blue Earth Diagnostics Announces Key Results from Phase 3 SPOTLIGHT Study of 18F-rhPSMA-7 3, an Investigational PET Imaging Agent, in Biochemical Recurrence of Prostate Cancer

BURLINGTON, Mass. & OXFORD, England (BUSINESS WIRE) Feb 15, 2022

United statesUnited kingdomDavid gaudenScintomics gmbGeorgina mowattDavidm schusterMike beyerPriscilla harlanEmory university school of medicineDrug administrationWinship cancer institute of emory universitySam brown incBracco groupTechnical university of munichNuclear medicineCorporate communications

Blue Earth Diagnostics Highlights Upcoming Presentation of Key Results from Phase 3 SPOTLIGHT Study of Targeted PET Imaging Agent 18F-rhPSMA-7 3 in Biochemically Recurrent Prostate Cancer

BURLINGTON, Mass. & OXFORD, England (BUSINESS WIRE) Feb 1, 2022

United statesUnited kingdomSan franciscoScintomics gmbGeorgina mowattDavidm schusterMike beyerPriscilla harlanWinship cancer institute of emory universitySam brown incBracco groupTechnical university of munichNuclear medicineCorporate communicationsBlue earth diagnostic medical affairsEarth diagnostics

Blue Earth Diagnostics Highlights Axumin (Fluciclovine F 18) Presentation at Upcoming 22nd Annual Scientific Meeting in Urologic Oncology (SUO)

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced a presentation on Axumin (fluciclovine

United kingdomKostenloser wertpapierhandelGeorgina mowattGeraldl andrioleMike beyerPriscilla harlanDivision of urologic surgerySociety of urologic oncologyAlvinj siteman cancer centerWashington university school of medicineDepartment of surgerySam brown incBracco groupNuclear medicineCorporate communicationsBlue earth diagnostics

vimarsana © 2020. All Rights Reserved.